-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on MBX Biosciences, Raises Price Target to $70

Benzinga·05/12/2026 13:51:57
Listen to the news
Barclays analyst Eliana Merle maintains MBX Biosciences (NASDAQ:MBX) with a Overweight and raises the price target from $66 to $70.